牛牛AI助理已提取核心訊息
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
NexImmune, Inc.已與Cantor Fitzgerald & Co. 和BTIG, LLC共同達成協議，自2024年2月2日起終止其受控股權發行SM銷售協議和相關的 “市場” 發行計劃（ATM計劃）。該協議最初於2022年6月披露，允許NexImmune以5000萬美元的總髮行價出售其普通股。在終止之前，NexImmune成功出售了127,396股股票，淨收益約爲510萬美元。銷售協議和自動櫃員機計劃的終止不涉及對公司的任何重大提前解僱處罰。2022年6月17日向美國證券交易委員會提交的8-K表格中提到了銷售協議的更多細節。
NexImmune, Inc.已與Cantor Fitzgerald & Co. 和BTIG, LLC共同達成協議，自2024年2月2日起終止其受控股權發行SM銷售協議和相關的 “市場” 發行計劃（ATM計劃）。該協議最初於2022年6月披露，允許NexImmune以5000萬美元的總髮行價出售其普通股。在終止之前，NexImmune成功出售了127,396股股票，淨收益約爲510萬美元。銷售協議和自動櫃員機計劃的終止不涉及對公司的任何重大提前解僱處罰。2022年6月17日向美國證券交易委員會提交的8-K表格中提到了銷售協議的更多細節。
有用
沒用